Opinion &amp; analysis

Virtual AI Nurses And The Future Of Chronic Disease Management

What’s in store for chronic disease management in the future? Tap into this informal discussion with health entrepreneur Julia Hu, founder of Lark Health, for a look at her views of what’s to come, including the use of artificial intelligence nursing.

March 6, 2019

Top 20 Pharma Ranks: As Some Move Up, Others Fall Down

Although the ranking of Scrip’s top 100 pharma companies remained largely the same as the previous year, there were some surprising moves up – and down – in rank for major players within pharma. Find out who in the top 20 moved, and in what direction, in this essential resource from In Vivo.

December 13, 2018

FDA investigator insights: Device makers forget about the humans who use their products

Device makers often fail to consider what happens once their product is in a patient’s hands, says a seasoned U.S. FDA investigator. She identifies seven common human-factor–usability–problems. Learn what they are so you can enhance compliance and patient safety.

May 31, 2018

Estee Lauder Is Revising Claims, Retesting Products After Internal Breakdown

Estée Lauder’s CEO revealed that “a small group of employees” was responsible for intentionally altering test results behind product claims. The shocking disclosure was mitigated by the fact that the problem was discovered internally. Nevertheless, stock tumbled following the announcement–but has largely recovered. Find out how the disclosure may affect Lauder moving forward, and learn how analysts reacted

May 16, 2018

AbbVie’s Skyrizi Poised To Enter Packed Psoriasis Market

AbbeVie is banking on the success of a possible simultaneous European/US launch of Skyrizi, its psoriasis drug, to bolster the company’s declining revenues in Europe. Read about how the company plans to use Skyrizi to bounce back from the genericization of its blockbuster Humira in this informative article.

March 4, 2019

Mail Order and Internet Pharmacy in Europe

$740.00

This 17-country study finds that continued growth of mobile technologies and e-commerce,combined with a more stable regulatory environment, are driving changes in the European mail order and Internet pharmacy market.

January 18, 2017

The Emergence Of IO

Immuno-oncology: spurred by the approval of first-generation checkpoint inhibitors in 2014, this important market has continued to grow exponentially, as deals are made not only around checkpoint inhibitors themselves, but also for related molecules and technologies to be used in synergy with them. Examine the origins of this important and growing area in this essential In Vivo report.

October 24, 2018

The Next New Thing In FDA Inspections: Poor Root Cause Investigations

As the pharmaceuticals industry gets its issues with data integrity under control, a new challenge has arisen, according to US FDA comments at a recent meeting of the International Society for Pharmaceutical Engineering. Find out how these out-of-specification investigation (OOS) issues are playing out, with expert reporting from Pink Sheet.

January 6, 2019

Let’s Make A Deal: Sanofi Regeneron Extend A Hand On Praluent, Express Scripts Takes It

Sanofi and Regeneron made an offer: They would drop the cost of their PCSK9 inhibitor Praluent (alirocumab) for improved access. Express Scripts took them up on it. Learn whether this deal will affect the high rejection rate for PCSK9 drugs. Find out whether this deal is a one-off or the start of a trend.

May 1, 2018

Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting

Is a suffix that distinguishes biosimilars and other biologic products necessary in adverse event reporting? The US FDA says yes, although to date, nearly every adverse event report received by the FDA have identified biosimilars simply by their brand names.

October 10, 2018

Sanofi’s New CEO Paul Hudson Poised To Write The Next Chapter

Less than one month into his new job, Sanofi CEO Paul Hudson shared his perspective on how he plans to build on Sanofi’s strengths and deliver needed changes. Scrip shares details about Sanofi’s leadership history and Hudson’s early priorities at the helm.

September 2, 2019

A Hangover Is A Disease, German Court Rules

Alcohol-related hangovers are genuine illnesses according to a recent ruling by a high-level German court. HBW looks at the case against a German wellness manufacturer for health claims made for its “anti-hangover” supplements and how deeming hangover’s a disease affects the outcome of the case.

September 2, 2019

Moving Medical Affairs To The Pharma Forefront

Senior medical affairs officials sat down at a roundtable discussion facilitated by the Boston Consulting Group to discuss the role of medical affairs along the pharma value chain. Take a look at the outcome of this discussion and explore the role and challenges of medical affairs in pharma.

August 29, 2018

Ranbaxy Brothers Arrested, Downward Spiral Intensifies

With the Singh brothers of Ranbaxy being arrested over allegations of financial fraud, Scrip looks at the history of issues at the company and how things appear headed even further downhill with Daiichi Sankyo also separately pursuing enforcement of damages against the brothers.

September 2, 2019